XVIVO reported second-quarter net sales of SEK 239 million, ahead of the average analyst projection of SEK 235.68 million. The company's top-line expanded 34% compared with the year-ago quarter, with organic growth of 36% measured in local currencies.
The quarter's performance was concentrated in product segments. XVIVO's thoracic segment was the primary engine of growth, with sales in that area increasing 53% in local currencies. The abdominal product line also contributed, posting a 26% sales rise in local currencies for the quarter.
Not all revenue streams moved higher. Services sales declined 25% in local currencies, a reduction that partially offset the gains recorded in product sales.
On the profitability side, XVIVO reported a net profit of SEK 16.30 million for the quarter, translating to earnings per share of SEK 0.52. Operating income for the period was SEK 25 million.
Management framed the results around continued adoption of the company’s technologies. XVIVO said it sees growth opportunities across its product portfolio and in key markets, and expects that increasing adoption of its solutions will drive future growth.
Financial and operational takeaways:
- Revenue beat: Net sales of SEK 239 million compared with the analyst average of SEK 235.68 million.
- Strong organic growth: 36% organic growth in local currencies for the quarter.
- Segment dynamics: Thoracic sales rose 53% in local currencies, abdominal sales rose 26% in local currencies, while services declined 25% in local currencies.
- Profitability: Net profit SEK 16.30 million; EPS SEK 0.52; operating income SEK 25 million.
The company’s statement highlights confidence in product adoption and market expansion as levers for growth, though the decline in services revenue indicates mixed performance across revenue streams. The reported figures present a clear picture of where the company’s momentum is concentrated and where it faces headwinds within the same reporting period.